查看购物车
  • Traditional Chinese
  • English
封面
市场调查报告书
商品编码
1831993

胜肽治疗市场规模、份额、趋势及预测（按类型、製造商类型、合成技术、给药途径、应用和地区），2025 年至 2033 年

Peptide Therapeutics Market Size, Share, Trends and Forecast by Type, Type of Manufacturer, Synthesis Technology, Routes of Administration, Application, and Region, 2025-2033
出版日期: | 出版商: IMARC | 英文 139 Pages | 商品交期: 2-3个工作天内

价格

2024年，全球胜肽类治疗药物市场规模达461.7亿美元。展望未来， IMARC Group预测，到2033年，该市场规模将达到918.7亿美元，2025-2033年期间的复合年增长率为7.55%。目前，北美占据市场主导地位，2024年将占据约40.9%的市场。癌症、代谢紊乱和传染病的发生率不断上升，推动了市场对有针对性和高效治疗的需求。肽合成技术、药物传输系统和生物利用度的提升正在加速肽类治疗药物的研究和商业应用。此外，有利的监管审批、生物製药投资的增加以及个人化医疗应用的不断拓展，都是提升胜肽类治疗药物市场份额的关键因素。

市场由持续的进步驱动，包括人工智慧 (AI) 和计算模型在胜肽药物发现中的整合，从而能够更快地识别生物活性序列并提高疗效。此外，不断扩大的代谢和传​​染病临床试验管道进一步增强了需求。除此之外，对製造能力的投资不断增加，包括固相胜肽合成 (SPPS) 和混合合成方法，正在促进具有成本效益的扩大规模并为市场提供动力。例如，2025 年 4 月 3 日，CordenPharma 宣布一项超过 10 亿欧元（约 11 亿美元）的策略投资，以扩大其全球胜肽生产能力。该公司的成长目标包括增加 26,000 平方米的製造空间和 30,000 公升的固相胜肽合成 (SPPS) 能力。此外，生物技术新创公司和大型製药公司之间的策略合作伙伴关係正在支持加速创新和商业化。

在美国，罕见疾病治疗市场正透过政府的定向措施蓬勃发展。根据行业报告，美国食品药物管理局 (FDA) 为部分临床试验提供资金支持，以帮助申办方开发罕见疾病药物。 2024 年 10 月，FDA 宣布将在 2024 财政年度资助七项新的临床研究，其中包括一项 3 期试验，四年内共拨款 1,720 万美元。这项公共部门投资增强了早期研发活动，为基于胜肽的罕见和复杂疾病疗法的发展创造了更有利的环境。此外，个人化医疗的日益普及也推动了对基于胜肽的精准疗法的需求。此外，拥有专业胜肽类药物研发能力的合约研究组织 (CRO) 和合约开发生产组织 (CDMO) 的蓬勃发展，使企业能够有效率地从临床前阶段推进到商业化阶段。此外，人们对微创给药的兴趣日益浓厚，推动了注射和透皮肽製剂的开发。除此之外，FDA 的支持性监管途径，包括针对胜肽候选药物的快速通道和突破性疗法认定，进一步加速了市场进入。

胜肽治疗市场趋势：

慢性病盛行率不断上升

癌症、糖尿病和心血管疾病等慢性疾病的日益普及是推动市场发展的主要因素。根据美国国家生物技术资讯中心 (NCBI) 预测，全球癌症病例将大幅增加，到 2050 年将达到 3,530 万例，比 2022 年预计的 2,000 万例增加 76.6%。胜肽以其高度特异性和靶向精准生物过程的能力而闻名，为慢性疾病提供了有前景的治疗选择，而慢性疾病通常需要长期有效的管理方案。同时，随着生活方式相关健康状况的增加和全球人口老化，对创新的标靶疗法需求也不断增长。肽疗法因其独特的作用机製而恰好满足了这一需求，与传统的小分子药物相比，它可以最大限度地减少副作用。此外，政府和製药业在研发 (R&D) 方面的投入推动了新型胜肽的创造，扩大了治疗的可能性。除此之外，胜肽合成、配方和递送方面的进步提高了它们的生物利用度和稳定性，这对市场产生了积极的影响，因此，肽治疗市场强劲增长，解决了慢性病管理中尚未满足的关键需求。

胜肽合成和递送技术的进展

胜肽合成和药物递送技术的不断进步，大大促进了胜肽疗法的开发和疗效。固相胜肽合成 (SPPS) 和自动化合成平台等创新技术简化了高品质胜肽的生产，使其更有效率且更具成本效益。此外，奈米颗粒製剂和透皮贴剂等改进的递送系统正在应对与胜肽稳定性和生物利用度相关的挑战，预计这将为胜肽疗法市场带来积极的前景。此外，这些技术创新不仅增强了胜肽的治疗潜力，也拓展了其在肿瘤学、内分泌学和免疫学等各个医学领域的应用。一份产业报告显示，2023 年至 2024 年间，ClinicalTrials.gov 网站上记录了近 200 项使用胜肽疫苗进行传染病、癌症预防和治疗的临床试验。随着这些技术的不断发展，预计将透过支持新型有效胜肽疗法的开发来推动市场发展。

个人化医疗日益受到关注

对个人化医疗的日益重视，正成为全球市场另一个重要的成长诱因。根据肽疗法市场分析，肽疗法市场的成长得益于个人化医疗，即根据基因、环境和生活方式因素为患者定製药物。胜肽尤其适合这种方法，因为它们可以针对个别患者特有的特定途径和生物标记进行设计。基因组学和生物标记物研究的兴起，有助于识别可能受益于胜肽疗法的患者群体。随着医疗保健系统越来越认识到个人化治疗在改善患者预后和最大限度地减少副作用方面的价值，预计肽疗法的需求将会上升。这种向个人化医疗的转变正在塑造製药业的未来格局。据 FDA 称，自 2014 年以来，所有新药批准中超过 25% 用于个人化治疗。一份行业报告强调，透过个人化治疗，85% 的高血压患者和 80% 的 2 型糖尿病患者达到了目标临床结果，而标准治疗下这一比例仅为 65%。

目录

第一章：前言

第二章：范围与方法

  • 研究目标
  • 利害关係人
  • 资料来源
    • 主要来源
    • 二手资料
  • 市场评估
    • 自下而上的方法
    • 自上而下的方法
  • 预测方法

第三章：执行摘要

第四章：简介

第五章：全球胜肽治疗市场

  • 市场概况
  • 市场表现
  • COVID-19的影响
  • 市场预测

第六章：市场细分：依类型

  • 创新的
  • 通用的

第七章：市场细分：依製造商类型

  • 外包
  • 内部

第八章：市场细分：依合成技术

  • 固相胜肽合成
  • 液相胜肽合成
  • 混合技术

第九章：市场分割：透过行政途径

  • 肠外
  • 口服
  • 其他的

第 10 章：市场区隔：按应用

  • 胃肠道疾病
  • 神经系统疾病
  • 代谢紊乱
  • 癌症
  • 其他的

第 11 章：市场区隔：按地区

  • 北美洲
    • 美国
    • 加拿大
  • 亚太
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲
    • 印尼
    • 其他的
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙
    • 俄罗斯
    • 其他的
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他的
  • 中东和非洲

第 12 章：SWOT 分析

第 13 章：价值链分析

第 14 章：波特五力分析

第 15 章：价格分析

第 16 章：竞争格局

  • 市场结构
  • 关键参与者
  • 关键参与者简介
    • Amgen Inc.
    • Apitope International NV
    • Arch Biopartners Inc.
    • AstraZeneca plc
    • Circle Pharma Inc.
    • Corden Pharma GmbH
    • F. Hoffmann-La Roche AG
    • Ipsen Group
    • Lonza Group AG
    • Novo Nordisk A/S
    • Pfizer Inc.
    • Teva Pharmaceuticals Industries Ltd.
    • Zealand Pharma A/S
Product Code: SR112025A4510

The global peptide therapeutics market size was valued at USD 46.17 Billion in 2024. Looking forward, IMARC Group estimates the market to reach USD 91.87 Billion by 2033, exhibiting a CAGR of 7.55% during 2025-2033. North America currently dominates the market, holding a significant market share of around 40.9% in 2024. The market is driven by the growing prevalence of cancer, metabolic disorders, and infectious diseases, prompting increased demand for targeted and efficient treatments. Advancements in peptide synthesis technologies, drug delivery systems, and bioavailability enhancements are accelerating research and commercial adoption. Additionally, favorable regulatory approvals, rising investments in biopharmaceutical, and expanding applications in personalized medicine are key factors augmenting the peptide therapeutic market share.

The market is driven by continual advancements, including the integration of artificial intelligence (AI) and computational modeling in peptide drug discovery, enabling faster identification of bioactive sequences with improved efficacy. Additionally, expanding clinical trial pipelines for metabolic and infectious diseases further reinforces demand. Besides this, growing investments in manufacturing capabilities, including solid-phase peptide synthesis (SPPS) and hybrid synthesis methods, are facilitating cost-effective scale-up and providing an impetus to the market. For instance, on April 3, 2025, CordenPharma announced a strategic investment of more than EUR 1 Billion (about USD 1.1 Billion) to expand its global peptide production capacity. The company's growth ambitions include adding 26,000 square meters of manufacturing space and 30,000 L of solid-phase peptide synthesis (SPPS) capability. Moreover, strategic partnerships between biotech startups and large pharmaceutical firms are supporting accelerated innovation and commercialization.

In the United States, the market is gaining momentum through targeted government initiatives aimed at rare disease treatment. According to industry reports, the U.S. FDA provides financial support for a select number of clinical trials to aid sponsors in developing medicinal products for rare conditions. In October 2024, the FDA announced funding for seven new clinical studies in fiscal year 2024, including one Phase 3 trial, with a total allocation of USD 17.2 Million over four years. This public sector investment enhances early-stage research and development activities, contributing to a more favorable environment for the advancement of peptide-based therapies addressing rare and complex diseases. Furthermore, the increasing prevalence of personalized medicine is also fueling the need for peptide-based precision therapies. In addition to this, the robust presence of CROs and CDMOs with specialized peptide capabilities allows companies to progress from preclinical to commercial stages efficiently. Also, rising interest in minimally invasive drug delivery has driven the development of injectable and transdermal peptide formulations. Apart from this, supportive FDA regulatory pathways, including fast-track and breakthrough therapy designations for peptide candidates, have further accelerated market entry.

Peptide Therapeutics Market Trends:

Increasing Prevalence of Chronic Diseases

The increasing prevalence of chronic diseases, such as cancer, diabetes, and cardiovascular conditions, is a primary factor providing an impetus to the market. According to the NCBI, global cancer cases are projected to rise significantly, reaching 35.3 million by 2050, representing a 76.6% increase over the expected 20 million cases in 2022. Peptides, known for their high specificity and ability to target precise biological processes, offer promising treatment options for chronic diseases, which often require long-term and effective management solutions. In line with this, with a rise in lifestyle-related health conditions and an aging global population, the demand for innovative, targeted therapies is on the rise. Peptide therapeutics align well with this need due to their unique mechanisms of action, which minimize side effects as compared to traditional small-molecule drugs. Moreover, government and pharmaceutical sector investments in research and development (R&D) drive the creation of novel peptides, expanding treatment possibilities. In addition to this, advancements in peptide synthesis, formulation, and delivery have enhanced their bioavailability and stability, which is positively impacting the market, Consequently, there is a robust peptide therapeutics market growth, addressing critical unmet needs in chronic disease management.

Advancements in Peptide Synthesis and Delivery Technologies

Continual advancements in peptide synthesis and drug delivery technologies are significantly supporting the development and efficacy of peptide therapeutics. Innovative techniques, such as solid-phase peptide synthesis (SPPS) and automated synthesis platforms, have streamlined the production of high-quality peptides, making them more efficient and cost-effective. Moreover, improved delivery systems, such as nanoparticle formulations and transdermal patches, are addressing challenges related to peptide stability and bioavailability, which is expected to create a positive peptide therapeutics market outlook. In addition to this, these technological innovations not only enhance the therapeutic potential of peptides but also expand their applications across various medical fields, including oncology, endocrinology, and immunology. According to an industry report, nearly 200 clinical trials employing peptide vaccines for infectious diseases, cancer prevention, and therapy were documented on ClinicalTrials.gov between 2023 and 2024. As these advancements continue to evolve, they are expected to propel the market by supporting the development of novel and effective peptide-based therapies.

Growing Focus on Personalized Medicine

The increasing emphasis on personalized medicine is acting as another major growth-inducing factor in the market across the globe. According to the peptide therapeutics market analysis, the market for peptide therapies is growing due to personalized medicine, which customizes medicines to patients based on genetic, environmental, and lifestyle factors. Peptides are particularly well-suited for this approach, as they can be designed to target specific pathways and biological markers unique to individual patients. The rise of genomics and biomarker research is facilitating the identification of patient populations that may benefit from peptide-based therapies. As healthcare systems increasingly recognize the value of personalized treatments in improving patient outcomes and minimizing side effects, the need for peptide therapeutics is expected to rise. This shift toward personalized medicine is shaping the future landscape of the pharmaceutical industry. Over 25% of all new drug approvals since 2014 have been used for personalized treatments, according to the FDA. An industry report highlights that 85% of hypertension patients and 80% of type 2 diabetes patients reached target clinical outcomes with personalized approaches, compared to 65% under standard treatments.

Peptide Therapeutics Industry Segmentation:

Analysis by Type:

  • Innovative
  • Generic

Innovative leads the market with around 64.0% of market share in 2024. These therapeutics are typically first-in-class or best-in-class drugs, characterized by novel mechanisms of action, enhanced targeting abilities, and improved pharmacokinetic profiles. Unlike generic or biosimilar peptides, innovative peptides are developed through advanced technologies such as solid-phase peptide synthesis, recombinant DNA methods, and peptide conjugation platforms. Their importance is underscored by their high therapeutic value across complex diseases, including cancer, metabolic disorders, and rare genetic conditions. Apart from this, pharmaceutical companies are extensively investing in research and development (R&D) for innovative peptides due to their potential for exclusivity and premium pricing. Furthermore, regulatory incentives like orphan drug designations and fast-track approvals have boosted their commercial viability. As the demand for precision medicine and biologically targeted therapies grows, the innovative segment remains a cornerstone for shaping the future trajectory of peptide drug development and commercialization.

Analysis by Type of Manufacturer:

  • Outsourced
  • In-house

In-house leads the market with around 64.4% of market share in 2024. In-house manufacturing offers pharmaceutical companies' greater control over production quality, timelines, and intellectual property. By maintaining internal capabilities, companies can ensure consistency in complex synthesis processes, particularly crucial for high-purity peptide drugs that require stringent quality standards. In-house facilities allow for tighter integration between research and development (R&D) and manufacturing, enabling faster transitions from clinical development to commercial production. This also enhances flexibility in scaling production based on demand and allows quicker implementation of process improvements or modifications. For companies developing innovative or proprietary peptides, in-house manufacturing safeguards sensitive formulations and reduces reliance on external partners. It also helps in managing regulatory compliance more effectively, especially for therapies targeting rare diseases or requiring specialized delivery methods. As peptide drugs become more complex and personalized, the role of in-house manufacturing is expected to expand in the market.

Analysis by Synthesis Technology:

  • Solid Phase Peptide Synthesis
  • Liquid Phase Peptide Synthesis
  • Hybrid Technology

Liquid phase peptide synthesis leads the market with around 44.3% of market share in 2024. It is an important technology to produce simple peptides at a large scale. This method, which involves synthesizing peptides in solution using soluble reactants, offers advantages such as better reaction monitoring, easier purification of intermediates, and cost-effectiveness for high-volume manufacturing. LPPS is especially useful when producing peptides that do not require complex modifications or sequences, making it a practical choice for established, off-patent therapeutic peptides or early-stage development. Despite the broader industry shift toward solid phase peptide synthesis (SPPS) for complex molecules, LPPS continues to be relevant due to its scalability, efficiency in batch processing, and lower reagent cost. Manufacturers with expertise in LPPS achieve high yields with consistent purity, which is critical for meeting regulatory standards. Its continued application reinforces its role as a foundational technology in the peptide production landscape.

Analysis by Routes of Administration:

  • Parenteral
  • Oral
  • Others

Parental leads the market with around 88.7% of market share in 2024. Administering peptides via injection, typically intravenous, subcutaneous, or intramuscular, ensures rapid absorption, controlled dosing, and optimal therapeutic concentration in the bloodstream. This route bypasses enzymatic degradation and first-pass metabolism, which are major limitations for oral formulations. In the market, parenteral delivery supports a wide range of treatments, including hormone regulation, cancer therapy, metabolic disorders, and rare disease management. Many blockbuster peptide drugs, such as insulin analogs and GLP-1 receptor agonists, rely on subcutaneous administration for long-term disease control. Advances in delivery devices, including auto-injectors and pre-filled syringes, have also improved patient compliance and convenience. As research continues into alternative delivery methods, parenteral administration remains the standard for ensuring therapeutic efficacy and safety of peptide-based treatments.

Analysis by Application:

  • Gastrointestinal Disorders
  • Neurological Disorders
  • Metabolic Disorders
  • Cancer
  • Others

Metabolic disorders lead the market with around 27.9% of market share in 2024 due to the rising global incidence of conditions like diabetes, obesity, and metabolic syndrome. Peptide-based drugs offer distinct advantages, such as high specificity, low toxicity, and the ability to modulate complex biological pathways, making them ideal for treating these disorders. One of the most notable examples is the widespread use of GLP-1 receptor agonists like semaglutide and liraglutide in managing type 2 diabetes and obesity. The demand for such treatments is accelerating as lifestyle-related metabolic diseases become more prevalent across both developed and emerging economies. Additionally, advancements in peptide synthesis and drug delivery systems are expanding the therapeutic potential of peptides, enhancing their stability and bioavailability. This has encouraged pharmaceutical companies to invest heavily in research and development (R&D) for peptide drugs targeting metabolic pathways, driving innovation and growth in this segment of market.

Regional Analysis:

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

In 2024, North America accounted for the largest market share of over 40.9% driven by a strong pharmaceutical industry, advanced healthcare infrastructure, and high research and development (R&D) investment. The region, particularly the United States, hosts a concentration of major biotech firms and research institutions actively developing peptide-based drugs for cancer, metabolic disorders, and rare diseases. Regulatory support from agencies like the FDA, along with streamlined approval pathways for orphan drugs and breakthrough therapies, has accelerated market entry for innovative peptides. Additionally, the region benefits from a high prevalence of chronic diseases, growing demand for personalized medicine, and favorable reimbursement structures that support the adoption of advanced therapies. The region also sees active collaborations between academic centers and pharmaceutical companies, encouraging continuous innovation in peptide drug development. With a strong clinical trial ecosystem and rising patient awareness, North America remains a key contributor to both the revenue and innovation pipeline of the global market.

Key Regional Takeaways:

United States Peptide Therapeutics Market Analysis

In 2024, the United States holds a substantial share of around 86.50% of the market share in North America. The market in the United States is primarily driven by increased research and development (R&D) investments by pharmaceutical and biotechnology companies. In line with this, the heightened presence of advanced healthcare infrastructure and supportive reimbursement frameworks is accelerating the clinical adoption of peptide-based therapies. The rising incidence of chronic illnesses, including metabolic and cardiovascular disorders, requiring precise and targeted treatment solutions, is supporting market demand. According to the American Heart Association's 2025 statistical report, the United States recorded 941,652 cardiovascular disease (CVD)-related deaths in 2022, marking an increase of over 10,000 deaths from the 931,578 reported in 2021. Furthermore, growing public and private funding for rare disease therapeutics, encouraging peptide-centric pipelines, is propelling growth in the market. The rapid integration of artificial intelligence and machine learning into drug discovery processes, enabling rapid identification of therapeutic peptide candidates, is contributing to industry innovation and market appeal. Similarly, numerous collaborations between academic institutions and industry players that augment translational research and commercialization prospects are strengthening market presence. Additionally, increased reliance on contract manufacturing organizations for scalable peptide production is optimizing supply chains and bolstering product sales.

Europe Peptide Therapeutics Market Analysis

The European market is experiencing growth due to strong regulatory incentives for orphan and specialty drugs, which are promoting innovation in peptide-based treatments. In accordance with this, increased funding through Horizon Europe and national research initiatives is accelerating the clinical development of peptide formulations. Similarly, the rising burden of age-related conditions, including osteoporosis and neurodegenerative diseases, is increasing the peptide therapeutics market demand. According to NCBI, the annual number of osteoporotic fractures in the European Union was estimated at 4.28 million in 2019 and is projected to rise to 5.34 million by 2034, indicating a significant increase in fracture-related healthcare needs across the region. The growing manufacturing footprint in countries such as Germany and Switzerland, enhancing production efficiency, is supporting market scalability. Furthermore, the rising number of EMA approvals for novel peptide drugs, improving accessibility and clinical adoption, is bolstering market reach. The rapid integration of peptide-based solutions into antimicrobial resistance (AMR) strategies aligned with EU health goals is further strengthening market demand. Besides this, robust academic research in peptide chemistry and translational science, fostering innovation pipelines, is expanding therapeutic potential in the market.

Asia Pacific Peptide Therapeutics Market Analysis

The market in the Asia Pacific is gaining momentum due to rising healthcare expenditure across emerging economies, improving access to specialized treatments. In addition to this, the increasing prevalence of lifestyle-related disorders, such as diabetes and obesity, requires targeted therapeutic approaches, which are also driving product demand. As per an industry report, India leads globally with 212 million people living with diabetes, surpassing China's 148 million. Also, India has the highest number of individuals over the age of 30 with untreated diabetes, estimated at 133 million, compared to 78 million in China. Similarly, the rapid scale-up of domestic pharmaceutical manufacturing in countries like India, China, and South Korea, enabling cost-efficient peptide production, is enhancing market competitiveness. Moreover, the ongoing establishment of regional research and development (R&D) centers by global pharmaceutical firms supporting innovation and technology exchange is strengthening the market landscape. Apart from this, growing public awareness of personalized medicine and preventive care, particularly in the urban population, is accelerating the product uptake across a range of treatment areas.

Latin America Peptide Therapeutics Market Analysis

In Latin America, the market is progressing, attributed to the increasing burden of chronic diseases such as diabetes and cardiovascular disorders. Similarly, significant improvements in regional healthcare systems, enhancing access to specialty therapies, are supporting the broader adoption of peptide-based drugs. The Federal Government of Brazil increased the Ministry of Health's budget for specialized treatments by 34% between 2022 and 2024, raising the allocation from BRL 54.9 Billion in 2022 (about USD 10.98 Billion) to BRL 74.7 Billion (about USD 14.94 Billion) in 2024. Furthermore, various collaborations between domestic pharmaceutical firms and global players, facilitating technology transfer and localized production, are strengthening market infrastructure. Moreover, active participation in international regulatory alignment efforts, reducing barriers to entry for innovative therapies, is streamlining approval processes and accelerating market expansion across the region.

Middle East and Africa Peptide Therapeutics Market Analysis

In the Middle East and Africa, the market is advancing, supported by the growing incidences of lifestyle-related diseases such as obesity and type 2 diabetes, particularly in urban centers. According to the World Obesity Federation, the number of obese adults in the Middle East and Africa is projected to increase by over 200%, rising from 11.8 million to 37.2 million by 2030. Additionally, a rise in government-led healthcare reforms and increased public investment in specialty medical services are improving access to advanced treatments in the market. The strategic expansion of pharmaceutical distribution networks across the Gulf and Sub-Saharan regions is enhancing product availability. Moreover, growing participation in international clinical research collaborations is fostering innovation and promoting the integration of peptide-based therapies into national treatment protocols.

Competitive Landscape:

The market is characterized by intense competition driven by technological advancements, growing demand for targeted treatments, and expanding therapeutic applications. Several players are focusing on innovative drug delivery methods, including oral, transdermal, and nanoparticle-based systems, to overcome challenges such as enzymatic degradation and short half-life. Biosynthetic techniques and solid-phase peptide synthesis are refined for scalability and cost efficiency. According to the peptide therapeutics market forecast, the sector is expected to grow steadily in the future years, driven by increased research and development (R&D) spending and favorable regulatory environments for biologics. Peptides have promising clinical applications in oncology, endocrinology, and infectious disorders. Market participants are also engaging in strategic collaborations, licensing deals, and contract manufacturing partnerships to strengthen their portfolios. The market landscape is further shaped by patent expiries, prompting an influx of generics and biosimilars. The emphasis is shifting toward long-acting and multifunctional peptides, reflecting the push for improved patient outcomes and competitive differentiation.

The report provides a comprehensive analysis of the competitive landscape in the peptide therapeutics market with detailed profiles of all major companies, including:

  • Amgen Inc.
  • Apitope International NV
  • Arch Biopartners Inc.
  • AstraZeneca plc
  • Circle Pharma Inc.
  • Corden Pharma GmbH
  • F. Hoffmann-La Roche AG
  • Ipsen Group
  • Lonza Group AG
  • Novo Nordisk A/S
  • Pfizer Inc.
  • Teva Pharmaceuticals Industries Ltd.
  • Zealand Pharma A/S

Key Questions Answered in This Report

  • 1.How big is the peptide therapeutics market?
  • 2.What is the future outlook of the peptide therapeutics market?
  • 3.What are the key factors driving the peptide therapeutics market?
  • 4.Which region accounts for the largest peptide therapeutics market?
  • 5.Which are the leading companies in the global peptide therapeutics market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Peptide Therapeutics Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Type

  • 6.1 Innovative
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Generic
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast

7 Market Breakup by Type of Manufacturer

  • 7.1 Outsourced
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 In-house
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast

8 Market Breakup by Synthesis Technology

  • 8.1 Solid Phase Peptide Synthesis
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Liquid Phase Peptide Synthesis
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Hybrid Technology
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast

9 Market Breakup by Routes of Administration

  • 9.1 Parenteral
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Oral
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Others
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast

10 Market Breakup by Application

  • 10.1 Gastrointestinal Disorders
    • 10.1.1 Market Trends
    • 10.1.2 Market Forecast
  • 10.2 Neurological Disorders
    • 10.2.1 Market Trends
    • 10.2.2 Market Forecast
  • 10.3 Metabolic Disorders
    • 10.3.1 Market Trends
    • 10.3.2 Market Forecast
  • 10.4 Cancer
    • 10.4.1 Market Trends
    • 10.4.2 Market Forecast
  • 10.5 Others
    • 10.5.1 Market Trends
    • 10.5.2 Market Forecast

11 Market Breakup by Region

  • 11.1 North America
    • 11.1.1 United States
      • 11.1.1.1 Market Trends
      • 11.1.1.2 Market Forecast
    • 11.1.2 Canada
      • 11.1.2.1 Market Trends
      • 11.1.2.2 Market Forecast
  • 11.2 Asia-Pacific
    • 11.2.1 China
      • 11.2.1.1 Market Trends
      • 11.2.1.2 Market Forecast
    • 11.2.2 Japan
      • 11.2.2.1 Market Trends
      • 11.2.2.2 Market Forecast
    • 11.2.3 India
      • 11.2.3.1 Market Trends
      • 11.2.3.2 Market Forecast
    • 11.2.4 South Korea
      • 11.2.4.1 Market Trends
      • 11.2.4.2 Market Forecast
    • 11.2.5 Australia
      • 11.2.5.1 Market Trends
      • 11.2.5.2 Market Forecast
    • 11.2.6 Indonesia
      • 11.2.6.1 Market Trends
      • 11.2.6.2 Market Forecast
    • 11.2.7 Others
      • 11.2.7.1 Market Trends
      • 11.2.7.2 Market Forecast
  • 11.3 Europe
    • 11.3.1 Germany
      • 11.3.1.1 Market Trends
      • 11.3.1.2 Market Forecast
    • 11.3.2 France
      • 11.3.2.1 Market Trends
      • 11.3.2.2 Market Forecast
    • 11.3.3 United Kingdom
      • 11.3.3.1 Market Trends
      • 11.3.3.2 Market Forecast
    • 11.3.4 Italy
      • 11.3.4.1 Market Trends
      • 11.3.4.2 Market Forecast
    • 11.3.5 Spain
      • 11.3.5.1 Market Trends
      • 11.3.5.2 Market Forecast
    • 11.3.6 Russia
      • 11.3.6.1 Market Trends
      • 11.3.6.2 Market Forecast
    • 11.3.7 Others
      • 11.3.7.1 Market Trends
      • 11.3.7.2 Market Forecast
  • 11.4 Latin America
    • 11.4.1 Brazil
      • 11.4.1.1 Market Trends
      • 11.4.1.2 Market Forecast
    • 11.4.2 Mexico
      • 11.4.2.1 Market Trends
      • 11.4.2.2 Market Forecast
    • 11.4.3 Others
      • 11.4.3.1 Market Trends
      • 11.4.3.2 Market Forecast
  • 11.5 Middle East and Africa
    • 11.5.1 Market Trends
    • 11.5.2 Market Breakup by Country
    • 11.5.3 Market Forecast

12 SWOT Analysis

  • 12.1 Overview
  • 12.2 Strengths
  • 12.3 Weaknesses
  • 12.4 Opportunities
  • 12.5 Threats

13 Value Chain Analysis

14 Porters Five Forces Analysis

  • 14.1 Overview
  • 14.2 Bargaining Power of Buyers
  • 14.3 Bargaining Power of Suppliers
  • 14.4 Degree of Competition
  • 14.5 Threat of New Entrants
  • 14.6 Threat of Substitutes

15 Price Analysis

16 Competitive Landscape

  • 16.1 Market Structure
  • 16.2 Key Players
  • 16.3 Profiles of Key Players
    • 16.3.1 Amgen Inc.
      • 16.3.1.1 Company Overview
      • 16.3.1.2 Product Portfolio
      • 16.3.1.3 Financials
      • 16.3.1.4 SWOT Analysis
    • 16.3.2 Apitope International NV
      • 16.3.2.1 Company Overview
      • 16.3.2.2 Product Portfolio
    • 16.3.3 Arch Biopartners Inc.
      • 16.3.3.1 Company Overview
      • 16.3.3.2 Product Portfolio
      • 16.3.3.3 Financials
    • 16.3.4 AstraZeneca plc
      • 16.3.4.1 Company Overview
      • 16.3.4.2 Product Portfolio
      • 16.3.4.3 Financials
      • 16.3.4.4 SWOT Analysis
    • 16.3.5 Circle Pharma Inc.
      • 16.3.5.1 Company Overview
      • 16.3.5.2 Product Portfolio
    • 16.3.6 Corden Pharma GmbH
      • 16.3.6.1 Company Overview
      • 16.3.6.2 Product Portfolio
    • 16.3.7 F. Hoffmann-La Roche AG
      • 16.3.7.1 Company Overview
      • 16.3.7.2 Product Portfolio
      • 16.3.7.3 SWOT Analysis
    • 16.3.8 Ipsen Group
      • 16.3.8.1 Company Overview
      • 16.3.8.2 Product Portfolio
      • 16.3.8.3 Financials
      • 16.3.8.4 SWOT Analysis
    • 16.3.9 Lonza Group AG
      • 16.3.9.1 Company Overview
      • 16.3.9.2 Product Portfolio
      • 16.3.9.3 Financials
      • 16.3.9.4 SWOT Analysis
    • 16.3.10 Novo Nordisk A/S
      • 16.3.10.1 Company Overview
      • 16.3.10.2 Product Portfolio
      • 16.3.10.3 Financials
      • 16.3.10.4 SWOT Analysis
    • 16.3.11 Pfizer Inc.
      • 16.3.11.1 Company Overview
      • 16.3.11.2 Product Portfolio
      • 16.3.11.3 Financials
      • 16.3.11.4 SWOT Analysis
    • 16.3.12 Teva Pharmaceuticals Industries Ltd.
      • 16.3.12.1 Company Overview
      • 16.3.12.2 Product Portfolio
      • 16.3.12.3 Financials
      • 16.3.12.4 SWOT Analysis
    • 16.3.13 Zealand Pharma A/S
      • 16.3.13.1 Company Overview
      • 16.3.13.2 Product Portfolio
      • 16.3.13.3 Financials

List of Figures

  • Figure 1: Global: Peptide Therapeutics Market: Major Drivers and Challenges
  • Figure 2: Global: Peptide Therapeutics Market: Sales Value (in Billion USD), 2019-2024
  • Figure 3: Global: Peptide Therapeutics Market Forecast: Sales Value (in Billion USD), 2025-2033
  • Figure 4: Global: Peptide Therapeutics Market: Breakup by Type (in %), 2024
  • Figure 5: Global: Peptide Therapeutics Market: Breakup by Type of Manufacturer (in %), 2024
  • Figure 6: Global: Peptide Therapeutics Market: Breakup by Synthesis Technology (in %), 2024
  • Figure 7: Global: Peptide Therapeutics Market: Breakup by Routes of Administration (in %), 2024
  • Figure 8: Global: Peptide Therapeutics Market: Breakup by Application (in %), 2024
  • Figure 9: Global: Peptide Therapeutics Market: Breakup by Region (in %), 2024
  • Figure 10: Global: Peptide Therapeutics (Innovative) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 11: Global: Peptide Therapeutics (Innovative) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 12: Global: Peptide Therapeutics (Generic) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 13: Global: Peptide Therapeutics (Generic) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 14: Global: Peptide Therapeutics (Outsourced) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 15: Global: Peptide Therapeutics (Outsourced) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 16: Global: Peptide Therapeutics (In-house) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 17: Global: Peptide Therapeutics (In-house) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 18: Global: Peptide Therapeutics (Solid Phase Peptide Synthesis) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 19: Global: Peptide Therapeutics (Solid Phase Peptide Synthesis) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 20: Global: Peptide Therapeutics (Liquid Phase Peptide Synthesis) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 21: Global: Peptide Therapeutics (Liquid Phase Peptide Synthesis) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 22: Global: Peptide Therapeutics (Hybrid Technology) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 23: Global: Peptide Therapeutics (Hybrid Technology) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 24: Global: Peptide Therapeutics (Parenteral) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 25: Global: Peptide Therapeutics (Parenteral) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 26: Global: Peptide Therapeutics (Oral) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 27: Global: Peptide Therapeutics (Oral) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 28: Global: Peptide Therapeutics (Other Routes of Administration) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 29: Global: Peptide Therapeutics (Other Routes of Administration) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 30: Global: Peptide Therapeutics (Gastrointestinal Disorders) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 31: Global: Peptide Therapeutics (Gastrointestinal Disorders) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 32: Global: Peptide Therapeutics (Neurological Disorders) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 33: Global: Peptide Therapeutics (Neurological Disorders) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 34: Global: Peptide Therapeutics (Metabolic Disorders) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 35: Global: Peptide Therapeutics (Metabolic Disorders) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 36: Global: Peptide Therapeutics (Cancer) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 37: Global: Peptide Therapeutics (Cancer) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 38: Global: Peptide Therapeutics (Other Applications) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 39: Global: Peptide Therapeutics (Other Applications) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 40: North America: Peptide Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 41: North America: Peptide Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 42: United States: Peptide Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 43: United States: Peptide Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 44: Canada: Peptide Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 45: Canada: Peptide Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 46: Asia-Pacific: Peptide Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 47: Asia-Pacific: Peptide Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 48: China: Peptide Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 49: China: Peptide Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 50: Japan: Peptide Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 51: Japan: Peptide Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 52: India: Peptide Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 53: India: Peptide Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 54: South Korea: Peptide Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 55: South Korea: Peptide Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 56: Australia: Peptide Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 57: Australia: Peptide Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 58: Indonesia: Peptide Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 59: Indonesia: Peptide Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 60: Others: Peptide Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 61: Others: Peptide Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 62: Europe: Peptide Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 63: Europe: Peptide Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 64: Germany: Peptide Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 65: Germany: Peptide Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 66: France: Peptide Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 67: France: Peptide Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 68: United Kingdom: Peptide Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 69: United Kingdom: Peptide Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 70: Italy: Peptide Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 71: Italy: Peptide Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 72: Spain: Peptide Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 73: Spain: Peptide Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 74: Russia: Peptide Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 75: Russia: Peptide Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 76: Others: Peptide Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 77: Others: Peptide Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 78: Latin America: Peptide Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 79: Latin America: Peptide Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 80: Brazil: Peptide Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 81: Brazil: Peptide Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 82: Mexico: Peptide Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 83: Mexico: Peptide Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 84: Others: Peptide Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 85: Others: Peptide Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 86: Middle East and Africa: Peptide Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 87: Middle East and Africa: Peptide Therapeutics Market: Breakup by Country (in %), 2024
  • Figure 88: Middle East and Africa: Peptide Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 89: Global: Peptide Therapeutics Industry: SWOT Analysis
  • Figure 90: Global: Peptide Therapeutics Industry: Value Chain Analysis
  • Figure 91: Global: Peptide Therapeutics Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Peptide Therapeutics Market: Key Industry Highlights, 2024 and 2033
  • Table 2: Global: Peptide Therapeutics Market Forecast: Breakup by Type (in Million USD), 2025-2033
  • Table 3: Global: Peptide Therapeutics Market Forecast: Breakup by Type of Manufacturer (in Million USD), 2025-2033
  • Table 4: Global: Peptide Therapeutics Market Forecast: Breakup by Synthesis Technology (in Million USD), 2025-2033
  • Table 5: Global: Peptide Therapeutics Market Forecast: Breakup by Routes of Administration (in Million USD), 2025-2033
  • Table 6: Global: Peptide Therapeutics Market Forecast: Breakup by Application (in Million USD), 2025-2033
  • Table 7: Global: Peptide Therapeutics Market Forecast: Breakup by Region (in Million USD), 2025-2033
  • Table 8: Global: Peptide Therapeutics Market: Competitive Structure
  • Table 9: Global: Peptide Therapeutics Market: Key Players